Votre panier est vide
Commencez à ajouter des peptides de recherche à votre panier.
PARCOURIR LES PRODUITSSingle and Dual Incretin Metabolic Optimization
12-16 weeks
Once weekly subcutaneous injection
2 peptides
The metabolic support protocol leverages both single-incretin (Semaglutide, GLP-1 RA) and dual-incretin (Tirzepatide, GIP/GLP-1 RA) receptor agonists for comprehensive metabolic research applications. This protocol enables researchers to compare single vs dual pathway activation, investigate dose-response relationships, and study the metabolic effects that have produced unprecedented clinical trial results. Both compounds are supplied as high-purity lyophilized vials from Peptides Pharma, reconstituted with bacteriostatic water for precise dose titration. This protocol is intended for research purposes and does not constitute medical advice.
Semaglutide activates GLP-1 receptors, slowing gastric emptying, enhancing glucose-dependent insulin secretion, and suppressing glucagon release. Tirzepatide's dual mechanism engages both GIP and GLP-1 pathways — GIP receptor activation complements GLP-1 effects by improving beta-cell function, enhancing lipid metabolism, and modulating adipose tissue distribution. The combination allows researchers to study additive and potentially synergistic metabolic effects: improved insulin sensitivity, reduced hepatic lipogenesis, appetite modulation via hypothalamic signaling, and favorable shifts in body composition. Once-weekly dosing reflects the engineered extended half-lives of both compounds.
Get This Protocol
2 products from 246,56 €
Tirzepatide activates both GIP and GLP-1 receptors, whereas Semaglutide targets only GLP-1. Clinical data shows this dual mechanism produces greater metabolic improvements, with SURPASS-2 demonstrating Tirzepatide's superiority over Semaglutide in both HbA1c reduction and weight loss at comparable doses. GIP receptor activation adds unique benefits for lipid metabolism and adipose tissue remodeling.
Both Semaglutide and Tirzepatide clinical trials used graduated dose titration (starting low and escalating every 4 weeks) to optimize tolerability. The 12-16 week timeframe allows for full dose escalation and sufficient time at target dose to observe metabolic endpoints. Longer protocols (up to 72 weeks) produced maximum effects in clinical trials.
Published research tracks fasting glucose, HbA1c, fasting insulin, HOMA-IR (insulin resistance), triglycerides, LDL/HDL cholesterol, liver enzymes (ALT/AST), body composition (DEXA), and inflammatory markers (hsCRP). These biomarkers provide a comprehensive metabolic profile.
Yes. All major clinical trials employed dose titration to manage GI tolerability. The standard titration starts at the lowest available dose, increasing every 4 weeks to the target maintenance dose. Rapid escalation without titration significantly increased nausea and other GI side effects in clinical data.
Both Semaglutide and Tirzepatide are supplied as lyophilized powder in sealed vials. Reconstitute with bacteriostatic water according to the included instructions. The reconstituted solution is administered via weekly subcutaneous injection. Store reconstituted vials refrigerated and use within the recommended timeframe.
Legal under MHRA rules. BPC-157, tirzepatide & NAD+ vials with worldwide delivery from £99. >99% purity, GMP certified, COA included.
ARTICLEPens cut dosing error from 15% to under 2%. We compare accuracy, contamination risk, cost, and convenience. See why researchers are switching in 2026.
ARTICLEOver 100 published studies back BPC-157 for tissue repair, gut healing, and neuroprotection. Mechanisms, dosing protocols, and where to buy in the UK.
COMPARISONCompare semaglutide and tirzepatide for metabolic research. Single vs dual receptor, efficacy data, side effects, and dosing. Buy research-grade peptide vials.
COMPARISONCompare semaglutide and AOD-9604 for weight management research. GLP-1 signalling vs lipolytic peptide mechanisms. Buy >99% purity research-grade peptides.
ENCYCLOPEDIAGLP-1 Receptor Agonist (Incretin Mimetic). Molecular weight: 4113.58 Da. Explore mechanism of action, key studies, and research applications.
BUNDLEDual-incretin approach for comprehensive metabolic research
PROTOCOLResearch protocol for Semaglutide and Tirzepatide lyophilized vials investigating GLP-1 and dual GIP/GLP-1 receptor agonism. Explore metabolic mechanisms, dose titration, and landmark clinical trial data.
FAQSemaglutide research FAQ. Learn about GLP-1 receptor agonist mechanisms, metabolic research, purity, storage, reconstitution, and research applications.
CATEGORYResearch-grade recovery research vials. BPC-157 and TB-500 for tissue repair, wound healing, and inflammation research. >99% purity, UK delivery.
CATEGORYResearch-grade weight loss research vials. Tirzepatide dual GIP/GLP-1 agonist for metabolic research. Lyophilized vials, >99% purity, worldwide delivery.
All Peptides Pharma research vials are pre-mixed, >99% purity, GMP manufactured with worldwide delivery.
FOR RESEARCH PURPOSES ONLY. NOT INTENDED FOR SELF-ADMINISTRATION.
SHOP RESEARCH VIALS